Opioid Dependence Treatment Market size is estimated to reach ~USD 7 billion by the end of 2035 by growing at a CAGR of ~9% over the forecast period, i.e., 2023 – 2035. In addition to this, in the year 2022, the market size of opioid dependence treatment was ~USD 3 Billion. The growth of this market is driven by the increasing number of people all over the world getting addicted to opioids. This number has been increasing at a steady pace over the years. According to the World Health Organization (WHO), there were approximately 53 million opioid users worldwide in 2019. This has increased the demand for opioid addiction treatment.
Moreover, the market is also anticipated to grow with rising government initiatives regarding opioid dependency treatment. The government authorities of various regions across the globe time and again have identified the need for an opioid shortage and have adopted multiple initiatives and programs to promote opioid dependency treatment all over the world. In the United States, the Substance Abuse and Mental Health Services Administration (SAMHSA) has allocated funds to support drug-assisted treatment (MAT) for opioid addiction.
Base Year |
2022 |
Forecast Year |
2023 - 2035 |
CAGR |
~9% |
Base Year Market Size (2022) |
~USD 3 billion |
Forecast Year Market Size (2035) |
~USD 7 billion |
Regional Scope |
|
Growth Drivers
Challenges
The global opioid dependence treatment market is segmented and analyzed for demand and supply by drug cases into naloxone, buprenorphine, and methadone. Out of these, the buprenorphine segment is anticipated to hold the largest market share by the end of 2035. This can be attributed to the high demand for these drugs in the developed market such as the US and France. In the United States, buprenorphine is approved by the Food and Drug Administration (FDA) for the treatment of opioid addiction. In 2019, more than 1.3 million buprenorphine prescriptions were issued in the United States. Moreover, the buprenorphine segment has grown in recent years as more healthcare providers recognize the benefits of MAT or medication-assisted treatment of opioid addiction.
The global opioid dependence treatment market is segmented and analyzed for demand and supply by sales channel into retail pharmacies, online pharmacies, hospitals, and rehabilitation centers. Out of these, the hospital segment is anticipated to hold the largest market share by the end of 2035. Treatment for opioid dependence is often given in hospitals, especially for individuals who need inpatient treatment or detoxification. Hospitals can also provide outpatient care and aftercare services to people who have completed inpatient care. This is expected to drive the growth of this segment in the forecast period.
Our in-depth analysis of the global opioid dependence treatment market includes the following segments:
By Drug Cases |
|
By Sales Channel |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this Report
The opioid dependence treatment market in Asia Pacific is estimated to witness noteworthy growth over the forecast period. This can be attributed on the back of the growing awareness among the general population about opioid use disorder, and the large patient pool in the region. According to estimates the prevalence of opioid use disorder in the Asia-Pacific region at 0.3% to 0.6% of the population, with some countries such as Thailand and Myanmar reporting higher rates. The market growth is fueled by increasing demand for drug-assisted treatment (MAT), which combines pharmacotherapy with counseling and behavioral therapy to help recover from opioid addiction. Several countries in the region have also taken steps to expand access to opioid addiction treatment. In India, for instance, the government has launched a program to provide free opioid replacement therapy (OST) to injecting drug users. In Thailand, the government has set up methadone clinics to provide drug-assisted treatment for opioid addicts.
Moreover, the opioid dependence treatment market in North America is expected to acquire the largest share during the forecast period. This can be attributed owing to the increasing number of people suffering from opioid dependency, and the high emphasis of government to tackle the same. As per the U.S. Department of Health and Human Services, in a survey conducted in 2019, 10.1 million people aged 12 years or older misused opioids in 2018, whereas 9.7 million people misused prescribed pain relievers. In addition, high healthcare spending is also projected to boost market growth in the region in the coming years. In addition to MAT, other treatment options for opioid addiction include detox programs, behavioral therapy, and support groups. The market for these treatments is also growing in North America as more people seek help with their opioid addiction. Several countries in North America have also taken steps to expand access to opioid addiction treatment. For example, in the United States, the government has launched initiatives to expand access to his MAT, increase funding for addiction treatment programs, and improve addiction education for providers. Overall, the North American opioid addiction treatment market represents a huge opportunity for healthcare providers and pharmaceutical companies. However, more efforts are needed to tackle the opioid epidemic and improve access to effective, evidence-based treatment options.
The opioid dependence treatment market in Europe region is estimated to account for a significant market share in the forecast period. The market is driven by a combination of factors such as the increasing prevalence of opioid dependence, growing awareness of the need for treatment, and favorable reimbursement policies. Several European countries have also taken steps to expand access to opioid addiction treatment. For instance, in the UK, the government has launched an initiative to expand access to naloxone, a drug used to curb opioid overdoses. In Germany, the government has established a program to provide opioid replacement therapy (OST) for people with opioid dependence. Overall, the European opioid addiction treatment market represents a huge opportunity for healthcare providers and pharmaceutical companies.
Author Credits: Radhika Gupta, Shivam Bhutani
Ans: The major factors driving the market growth are the increasing number of cases of opioid abuse and addictions among people worldwide and favorable reimbursements for smoking cessation therapy.
Ans: The market size of opioid dependence treatment is anticipated to attain a CAGR of ~9% over the forecast period, i.e., 2023 – 2035.
Ans: Side effects of opioid use disorder drugs are estimated to hamper the market growth.
Ans: North America is estimated to create notable growth opportunities for market growth over the forecast period.
Ans: The major players in the market are Orexo AB, Indivior PLC, Titan Pharmaceuticals, Inc., Viatris Inc., Pfizer, Inc., and Others.
Ans: The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.
Ans: The market is segmented by drug class, sales channel, and region.
Ans: The hospital segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?